Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 4.8% – Should You Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price was down 4.8% on Monday . The stock traded as low as $44.86 and last traded at $45.26. 355,374 shares were traded during mid-day trading, an increase of 13% from the average session volume of 315,698 shares. The stock had previously closed at $47.55.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on COAG. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Jefferies Financial Group increased their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Finally, Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.00.

Hemab Therapeutics Trading Down 2.2%

The stock has a market capitalization of $2.17 billion and a price-to-earnings ratio of -1.94. The business’s 50-day simple moving average is $34.43.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders bought 295,541 shares of company stock valued at $7,309,603 over the last quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.